Greater than two in 5 (42%), or 57.4 million adults beneath age 65 with personal insurance coverage, might qualify based mostly on scientific standards for GLP-1 medication used to deal with individuals with sort 2 diabetes, weight problems or obese, and weight-related well being circumstances, in accordance with a brand new KFF evaluation.

Though solely about 3% of adults with employer protection had a prescription in 2022, demand for and spending on GLP-1 medication has grown and should proceed to develop. Given the excessive value and excessive demand for these medication, employers and insurers might proceed to impose stricter eligibility necessities for protection than the scientific indications set by the Meals and Drug Administration.

The complete evaluation and different well being care value information can be found on the Peterson-KFF Well being System Tracker, an internet data heart designed to watch and assess the efficiency of the U.S. well being care system.